FARN.L
Strong SellSinkerFaron Pharmaceuticals Oy · Healthcare · Finland · $95M · Avg Vol: $21K/d
Sinker: Weak, expensive and falling. Nothing here to keep it afloat.
ABOUT FARON PHARMACEUTICALS OY
Read
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for cancers with high unmet needs, notably its lead candidate bexmarilimab. The company targets the myeloid cell receptor Clever-1 to overcome resistance to existing immunotherapies, carving out a unique therapeutic niche. It is a high-risk, high-reward clinical-stage biotech developer in the oncology space.
FINANCIAL SUMMARY (GBP)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — |
| EPS (GBp) | -13.20 | -14.01 | -22.96 | -20.66 | — | -10.09 |
| Shares | 202.9M | 202.9M | 113.8M | 124.4M | -38.7% | — |
| Debt | 11.4M | 11.3M | 10.4M | 21.2M | 23.0% | 15.5M |
| Equity | -9.9M | -13.1M | -8.4M | -15.9M | — | — |
| Op CF | -19.8M | -20.5M | -19.2M | -15.4M | — | -17.4M |
| Inv CF | -0.3M | -0.1M | 0.1M | -17.2K | — | — |
| Fin CF | 20.2M | 20.6M | 21.3M | 17.8M | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of FARN.L are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| FARN.L | Faron Pharmaceuticals Oy(you) | $95M | 7 | Strong Sell |
| HRTIS.HE | Herantis Pharma Oyj | $51M | 5 | Strong Sell |
| NANOFH.HE | Nanoform Finland Oyj | $86M | 31 | Sell |
| AIFORIA.HE | Aiforia Technologies Oyj | $74M | 3 | Strong Sell |
| HEALTH.HE | Nightingale Health Oyj | $65M | 13 | Strong Sell |
| OPTOMED.HE | Optomed Oyj | $59M | 16 | Strong Sell |
| NXTMH.HE | Nexstim Plc | $79M | 27 | Sell |
| MODU.HE | Modulight Oyj | $51M | 32 | Sell |
| REG1V.HE | Revenio Group Oyj | $435M | 44 | Hold |
| ORIOLA.HE | Oriola Oyj | $191M | 67 | Buy |
Peer medians: ROE -14.3% · P/E 19.5x · Gross margin 65.9%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.